Seribantumab

Seribantumab (MM 121) is a fully human IgG2 monoclonal antibody that targets HER3. Seribantumab blocks the activation of epidermal growth factor receptor (ErbB) family members and its downstream signal. Seribantumab inhibits neuregulin 1 (NRG1) fusion-dependent tumorigenesis in vitro and in vivo in breast, lung and ovarian patient-derived cancer models[1].

Product Specifications

CAS Number

[1334296-12-6]

Product Name Alternative

SAR 256212; MM 121; Anti-Human ERBB3/ErbB 3 Recombinant Antibody

UNSPSC

12352203

Hazard Statement

H302, H315, H319, H335

Target

Apoptosis; EGFR

Type

Inhibitory Antibodies

Related Pathways

Apoptosis; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/seribantumab.html

Purity

96.043

Solubility

10 mM in DMSO

Smiles

[Seribantumab]

Molecular Weight

(143.14 kDa)

Precautions

H302, H315, H319, H335

References & Citations

[1]Odintsov I, et al. The Anti-HER3 mAb Seribantumab Effectively Inhibits Growth of Patient-Derived and Isogenic Cell Line and Xenograft Models with Oncogenic NRG1 Fusions. Clin Cancer Res. 2021 Jun 1;27 (11) :3154-3166.